Fig. 1From: Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRITumour growth within 20 days in Groups 1, 2, 3 and 4. Seven rats were measured and averaged in each group. The smallest tumour volume with the highest tumour inhibition rate was observed in Group 4 at the end of treatment, followed by Groups 3, 2, and 1. *P < 0.05, **P < 0.01, and ***P < 0.001 were generated from comparisons between the four groups at each time point using one-way analysis of varianceBack to article page